## Marc Ansari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7012887/publications.pdf Version: 2024-02-01



MADE ANSADI

#	Article	IF	CITATIONS
1	<i>In silico</i> and <i>in vitro</i> investigations on the protein–protein interactions of glutathione S-transferases with mitogen-activated protein kinase 8 and apoptosis signal-regulating kinase 1. Journal of Biomolecular Structure and Dynamics, 2022, 40, 1430-1440.	2.0	6
2	To be or not to be in the social media arena? The perspective of healthcare providers working within adolescent and young adult oncology in Switzerland. International Journal of Adolescent Medicine and Health, 2022, 34, 417-429.	0.6	4
3	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. Pharmacogenomics Journal, 2022, 22, 9-18.	0.9	1
4	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 196-202.	0.6	12
5	Cohort-based association study of germline genetic variants with acute and chronic health complications of childhood cancer and its treatment: Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study protocol. BMJ Open, 2022, 12, e052131.	0.8	1
6	A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation. BMC Molecular and Cell Biology, 2022, 23, 5.	1.0	1
7	Effect of Centralization on Surgical Outcome of Children Operated for Liver Tumors in Switzerland: A Retrospective Comparative Study. Children, 2022, 9, 217.	0.6	Ο
8	Covid-19 and beyond: Broadening horizons about social media use in oncology. A survey study with healthcare professionals caring for youth with cancer. Health Policy and Technology, 2022, 11, 100610.	1.3	4
9	Long-term follow-up for childhood cancer survivors: the Geneva experience. , 2022, 152, w30153.		1
10	Severity of hearing loss after platinum chemotherapy in childhood cancer survivors. Pediatric Blood and Cancer, 2022, 69, .	0.8	5
11	ABO incompatibile graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90.	1.3	3
12	Hypergonadotropic hypogonadism after ovarian tissue cryopreservation on a 13-year-old female: A case report and review of the literature. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102029.	0.6	1
13	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	0.8	163
14	Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation—a cohort study. Bone Marrow Transplantation, 2021, 56, 1065-1076.	1.3	3
15	Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. Annals of Hematology, 2021, 100, 209-216.	0.8	13
16	Pediatric Acute B-Cell Lymphoblastic Leukemia Developing Following Recent SARS-CoV-2 Infection. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, e1177-e1180.	0.3	4
17	Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer – A national cohort study. European Journal of Cancer, 2021, 145, 71-80.	1.3	8
18	Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls. Journal of Pediatric Hematology/Oncology, 2021, 43, e867-e872.	0.3	2

#	Article	IF	CITATIONS
19	Stem Cell Transplantation for Diamond–Blackfan Anemia. A Retrospective Study on Behalf of the Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). Transplantation and Cellular Therapy, 2021, 27, 274.e1-274.e5.	0.6	14
20	The analysis of GSTA1 promoter genetic and functional diversity of human populations. Scientific Reports, 2021, 11, 5038.	1.6	9
21	Birth characteristics and childhood leukemia in Switzerland: a register-based case–control study. Cancer Causes and Control, 2021, 32, 713-723.	0.8	6
22	Genetic Predictors for Sinusoidal Obstruction Syndrome—A Systematic Review. Journal of Personalized Medicine, 2021, 11, 347.	1.1	5
23	Dietary Intake and Diet Quality of Adult Survivors of Childhood Cancer and the General Population: Results from the SCCSS-Nutrition Study. Nutrients, 2021, 13, 1767.	1.7	3
24	Ketogenic diet treatment in diffuse intrinsic pontine glioma in children: Retrospective analysis of feasibility, safety, and survival data. Cancer Reports, 2021, 4, e1383.	0.6	10
25	A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 189.	3.5	23
26	Validation of questionnaire-reported chest wall abnormalities with a telephone interview in Swiss childhood cancer survivors. BMC Cancer, 2021, 21, 787.	1.1	1
27	Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT. Bone Marrow Transplantation, 2021, 56, 2697-2704.	1.3	2
28	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Pediatrics, 2021, 9, 705179.	0.9	22
29	Predicting fever in neutropenia with safetyâ€relevant events in children undergoing chemotherapy for cancer: The prospective multicenter SPOG 2015 FN Definition Study. Pediatric Blood and Cancer, 2021, 68, e29253.	0.8	3
30	Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1043-1056.	1.3	13
31	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	4
32	Trigeminal nerve chronic motor denervation caused by cerebellar peduncle pilocytic astrocytoma. Child's Nervous System, 2021, 37, 1035-1037.	0.6	0
33	Predictors for participation in DNA self-sampling of childhood cancer survivors in Switzerland. BMC Medical Research Methodology, 2021, 21, 236.	1.4	1
34	The Catalytic Activity of GSTM1 In vitro is Independent of MAPK8. Drug Metabolism Letters, 2021, 14, 163-165.	0.5	1
35	Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia. Frontiers in Pediatrics, 2021, 9, 775485.	0.9	6
36	Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children. Therapeutic Drug Monitoring, 2020, 42, 111-117.	1.0	13

#	Article	IF	CITATIONS
37	Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation. Leukemia, 2020, 34, 1422-1432.	3.3	20
38	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 920-927.	2.0	11
39	Sodium and Potassium Intakes and Cardiovascular Risk Profiles in Childhood Cancer Survivors: The SCCSS-Nutrition Study. Nutrients, 2020, 12, 57.	1.7	8
40	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer, 2020, 138, 212-224.	1.3	31
41	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 2020, 32, 106227.	0.5	2
42	The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. Lancet Haematology,the, 2020, 7, e902-e911.	2.2	18
43	The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers. Biomolecules, 2020, 10, 1112.	1.8	2
44	39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. The Lancet Child and Adolescent Health, 2020, 4, 495-502.	2.7	11
45	Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 1819-1827.	2.0	8
46	The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. Pediatric Blood and Cancer, 2020, 67, e28350.	0.8	29
47	Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. Blood Advances, 2020, 4, 1760-1769.	2.5	27
48	Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman–Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT). Bone Marrow Transplantation, 2020, 55, 1796-1809.	1.3	25
49	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, 55, 1540-1551.	1.3	42
50	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective lâ€BFM analysis of 333 children. British Journal of Haematology, 2020, 189, 745-750.	1.2	12
51	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020. 55. 1126-1136.	1.3	23
52	DIPG-25. KETOGENIC DIET IN DIFFUSE INTRINSIC PONTINE GLIOMA IN CHILDREN: A RETROSPECTIVE STUDY INVESTIGATING THE FEASIBILITY. Neuro-Oncology, 2020, 22, iii291-iii292.	0.6	0
53	Post-traumatic stress in parents of long-term childhood cancer survivors compared to parents of the Swiss general population. Journal of Psychosocial Oncology Research and Practice, 2020, 2, e024.	0.2	6
54	Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases. Journal of Visualized Experiments, 2020, , .	0.2	5

#	Article	IF	CITATIONS
55	Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. Swiss Medical Weekly, 2020, 150, w20375.	0.8	26
56	The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review. International Journal of Molecular Sciences, 2019, 20, 3889.	1.8	2
57	The conceptual understanding of pediatric palliative care: a Swiss healthcare perspective. BMC Palliative Care, 2019, 18, 55.	0.8	23
58	Temporal trends in incidence of childhood cancer in Switzerland, 1985–2014. Cancer Epidemiology, 2019, 61, 157-164.	0.8	20
59	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics, 2019, 20, 643-657.	0.6	65
60	4th ESPT Conference: pharmacogenomics and personalized medicine– research progress and clinical implementation. Pharmacogenomics, 2019, 20, 1063-1069.	0.6	1
61	Occurrence of highâ€grade glioma in Noonan syndrome: Report of two cases. Pediatric Blood and Cancer, 2019, 66, e27625.	0.8	11
62	Comment on: Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study. Pediatric Blood and Cancer, 2019, 66, e27664.	0.8	2
63	PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. Journal of Experimental and Clinical Cancer Research, 2019, 38, 69.	3.5	19
64	Activated Phosphoinositide 3 Kinase Delta Syndrome (APDS): A Primary Immunodeficiency Mimicking Lymphoma. Journal of Pediatric Hematology/Oncology, 2019, 41, e521-e524.	0.3	10
65	International survey on anticoagulation and antiplatelet strategies after pediatric liver transplantation. Pediatric Transplantation, 2019, 23, e13317.	0.5	14
66	Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor) Tj ETQq0 0 0 rgBT e14427.	/Overlock 0.5	10 Tf 50 307 3
67	Incorporation of <i>GSTA1</i> genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. British Journal of Clinical Pharmacology, 2018, 84, 1494-1504.	1.1	25
68	Palliative care in Swiss pediatric oncology settings: a retrospective analysis of medical records. Supportive Care in Cancer, 2018, 26, 2707-2715.	1.0	10
69	Burden of severe RSV disease among immunocompromised children and adults: a 10Âyear retrospective study. BMC Infectious Diseases, 2018, 18, 111.	1.3	55
70	Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. Pharmacogenomics Journal, 2018, 18, 64-69.	0.9	13
71	Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2018, 59, 590-600.	0.6	3
72	Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance. Therapeutic Drug Monitoring, 2018, 40, 84-92.	1.0	22

Marc Ansari

#	Article	IF	CITATIONS
73	MBCL-11. CONCURRENT IDH1 AND SMARCB1 MUTATIONS IN A PEDIATRIC MEDULLOBLASTOMA: A CASE REPORT. Neuro-Oncology, 2018, 20, i119-i119.	0.6	0
74	Role of advanced nurse practitioners in the care pathway for children diagnosed with leukemia. European Journal of Oncology Nursing, 2018, 36, 68-74.	0.9	7
75	Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report. Frontiers in Neurology, 2018, 9, 398.	1.1	10
76	Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children. PLoS ONE, 2018, 13, e0193862.	1.1	8
77	Patterns of paediatric end-of-life care: a chart review across different care settings in Switzerland. BMC Pediatrics, 2018, 18, 67.	0.7	28
78	Factors associated with immune hemolytic anemia after pediatric liver transplantation. Pediatric Transplantation, 2018, 22, e13230.	0.5	4
79	Monitoring pulmonary health in Swiss childhood cancer survivors. Pediatric Blood and Cancer, 2018, 65, e27255.	0.8	3
80	Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. New England Journal of Medicine, 2018, 378, 2376-2385.	13.9	217
81	Development and validation of an allele-specific PCR assay for genotyping a promoter and exonic single nucleotide polymorphisms of MGMT gene. Journal of Biological Methods, 2018, 5, e92.	1.0	2
82	Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997–2016. Swiss Medical Weekly, 2018, 148, w14589.	0.8	2
83	Parents' and Physicians' Perceptions of Children's Participation in Decision-making in Paediatric Oncology: A Quantitative Study. Journal of Bioethical Inquiry, 2017, 14, 555-565.	0.9	13
84	GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1918-1924.	2.0	16
85	11q deletion in neuroblastoma: a review of biological and clinical implications. Molecular Cancer, 2017, 16, 114.	7.9	96
86	Low adherence to dietary recommendations in adult childhood cancer survivors. Clinical Nutrition, 2017, 36, 1266-1274.	2.3	20
87	Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncology, The, 2017, 18, 122-131.	5.1	284
88	Better to know than to imagine: Including children in their health care. AJOB Empirical Bioethics, 2017, 8, 11-20.	0.8	35
89	Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT). Drug Metabolism and Personalized Therapy, 2017, 32, 173-174.	0.3	1
90	The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Pharmacology, 2017, 8, 451.	1.6	8

#	Article	IF	CITATIONS
91	High-grade glioma in very young children: a rare and particular patient population. Oncotarget, 2017, 8, 64564-64578.	0.8	38
92	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget, 2017, 8, 90852-90867.	0.8	39
93	Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study. Blood, 2017, 130, 911-911.	0.6	1
94	Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population. Drug Metabolism Letters, 2016, 10, 72-74.	0.5	3
95	Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use. International Journal of Molecular Sciences, 2016, 17, 1502.	1.8	27
96	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematology,the, 2016, 3, e526-e536.	2.2	197
97	Putting patient participation into practice in pediatrics—results from a qualitative study in pediatric oncology. European Journal of Pediatrics, 2016, 175, 1147-1155.	1.3	32
98	Detection of busulfan adducts on proteins. Rapid Communications in Mass Spectrometry, 2016, 30, 2517-2528.	0.7	3
99	Causeâ€specific longâ€term mortality in survivors of childhood cancer in <scp>S</scp> witzerland: A populationâ€based study. International Journal of Cancer, 2016, 139, 322-333.	2.3	62
100	The Role of Liver Transplantation in Undifferentiated Embryonal Sarcoma of the Liver in Children. Journal of Pediatric Hematology/Oncology, 2016, 38, 495-496.	0.3	3
101	Efficient Prophylaxis with Defibrotide for Sinusoidal Obstruction Syndrome (SOS) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2016, 128, 2204-2204.	0.6	6
102	Employment Situation of Parents of Long-Term Childhood Cancer Survivors. PLoS ONE, 2016, 11, e0151966.	1.1	28
103	Successful liver transplantation in a child with acuteâ€onâ€chronic liver failure and acquired thrombotic thrombocytopenic purpura. Liver Transplantation, 2015, 21, 704-706.	1.3	1
104	Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies. Bone Marrow Research, 2015, 2015, 1-6.	1.7	9
105	Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy. Pediatric Diabetes, 2015, 16, 138-145.	1.2	5
106	Ataxia-telangiectasia mutated ( <i>ATM</i> ) silencing promotes neuroblastoma progression through a <i>MYCN</i> independent mechanism. Oncotarget, 2015, 6, 18558-18576.	0.8	26
107	T-Cell Depletion Improves the Composite End Point Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 3204-3204.	0.6	0
108	GSTA1 Genotype Influences Performance of Initial Bu Prediction Methods during Conditioning before SCT. Blood, 2015, 126, 4323-4323.	0.6	0

#	Article	IF	CITATIONS
109	Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation. Therapeutic Drug Monitoring, 2014, 36, 93-99.	1.0	57
110	Adenovirus-induced Obstructive Uropathy With Acute Renal Failure in an Immunodeficient Child. Urology, 2014, 83, 217-219.	0.5	8
111	The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics Journal, 2014, 14, 263-271.	0.9	29
112	Validation of the Disease Risk Index for Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after T Cell Depletion. Biology of Blood and Marrow Transplantation, 2014, 20, 1322-1328.	2.0	13
113	Personalizing busulfan therapy for children undergoing hematopoietic stem cell transplantation. Personalized Medicine, 2014, 11, 463-466.	0.8	0
114	Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children. Current Drug Metabolism, 2014, 15, 251-264.	0.7	34
115	Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma. Virology Journal, 2013, 10, 191.	1.4	20
116	Pseudoprogression after proton beam irradiation for a choroid plexus carcinoma in pediatric patient: MRI and PET imaging patterns. Child's Nervous System, 2013, 29, 509-512.	0.6	12
117	Suivi des familles après le décès d'un enfant en oncohématologie pédiatriqueÂ: un besoinÂ?. Medecir Palliative, 2013, 12, 112-121.	<sup>۱е</sup> 0.0	0
118	Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. Bone Marrow Transplantation, 2013, 48, 939-946.	1.3	43
119	Is Acute Fibrinous and Organizing Pneumonia the Expression of Immune Dysregulation?. Journal of Pediatric Hematology/Oncology, 2013, 35, 139-143.	0.3	11
120	The Clinical Relevance of Pre-Formed Anti-HLA and Anti-MICA Antibodies after Cord Blood Transplantation in Children. PLoS ONE, 2013, 8, e72141.	1.1	22
121	Sulfolane (a metabolite of busulfan) Levels Could Predict Occurrence Of Hemorrhagic Cystitis In Children Receiving Busulfan Based Myeloablative Conditioning Before Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4574-4574.	0.6	0
122	Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity. Current Drug Metabolism, 2012, 13, 1196-1204.	0.7	12
123	A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography–tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 404, 1831-8.	1.9	12
124	A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2012, 26, 1437-1446.	0.7	39
125	Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia. European Journal of Clinical Pharmacology, 2012, 68, 887-888.	0.8	0
126	Secondary pulmonary alveolar proteinosis after unrelated cord blood hematopoietic cell transplantation. Pediatric Transplantation, 2012, 16, E146-9.	0.5	11

#	Article	IF	CITATIONS
127	Thirdâ€party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed postâ€hematopoietic stem cell transplantation. Pediatric Transplantation, 2012, 16, 131-136.	0.5	5
128	<i>GSTP1</i> hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. Genes Chromosomes and Cancer, 2012, 51, 174-185.	1.5	17
129	Association of Cth Genetic Variant with Veno-Occlusive Disease in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation Blood, 2012, 120, 3025-3025.	0.6	0
130	Do NK Cells Contribute to the Pathophysiology of Transplant-Associated Thrombotic Microangiopathy?. American Journal of Transplantation, 2011, 11, 1748-1752.	2.6	7
131	Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2011, 87, 138-147.	1.1	17
132	Primary Leptomeningeal Melanocytosis in a 10-Year-Old Girl. Journal of Child Neurology, 2011, 26, 1444-1448.	0.7	13
133	Myeloablative Conditioning with Pharmacokinetic-Targeted Intravenous Busulfan and Cyclophosphamide in Unrelated Cord Blood Transplantation for Myeloid Malignancies in Children. Blood, 2011, 118, 1965-1965.	0.6	0
134	ACUTE DISSEMINATED FATAL TOXOPLASMOSIS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION DESPITE ATOVAQUONE PROPHYLAXIS IN A YOUNG MAN. Pediatric Infectious Disease Journal, 2010, 29, 1059-1060.	1.1	11
135	DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2009, 15, 6931-6938.	3.2	34
136	Can the pharmacogenetics of <i>GST</i> gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?. Pharmacogenomics, 2009, 10, 1729-1732.	0.6	17
137	Response: MRP4 gene polymorphisms and treatment response in adult ALL. Blood, 2009, 114, 5401-5402.	0.6	6
138	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood, 2009, 114, 1383-1386.	0.6	83
139	IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies. Biology of Blood and Marrow Transplantation, 2008, 14, 576-582.	2.0	22
140	DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood, 2008, 111, 3692-3700.	0.6	104
141	Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Current Opinion in Pediatrics, 2007, 19, 15-22.	1.0	35
142	Pharmacogenomics of acute leukemia. Pharmacogenomics, 2007, 8, 817-834.	0.6	24
143	Cutaneous aspergillosis in a child with an acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2005, 45, 1005-1006.	0.8	1